Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
INmune BioINMB +1.06%58 3-Year EBITDA Growth Rate is 5.00% as of Mar. 2026. GuruFocus rates INMB with a GF Score™ of 58/100 and a GF Value™ of $1.79 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,135 Biotechnology companies, INmune Bio ranks worse than 63% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 5.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -4.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of INmune Bio was 5.00% per year. The lowest was -256.30% per year. And the median was -17.50% per year.
INmune Bio (NAS:INMB) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
INmune Bio 3-Year EBITDA Growth Rate Related Terms
INMB vs FLNA, DYAI, EXOZ: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, INmune Bio's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
INmune Bio 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, INmune Bio's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where INmune Bio's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 5.00% mean?
INmune Bio (INMB) has a 3-Year EBITDA Growth Rate of 5.00% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for INmune Bio and its competitors. According to the industry distribution chart, INmune Bio ranks #715 out of 1135 companies in the Biotechnology industry, placing it in the top 63%.
Is INmune Bio's 3-Year EBITDA Growth Rate too high?
INmune Bio's current 3-Year EBITDA Growth Rate is 5.00%. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.80. INmune Bio's value of 5.00% is 66.2% below this industry median. Based on the distribution chart, INmune Bio ranks #715 out of 1135 companies in the Biotechnology industry, which is below the industry midpoint. Overall, INmune Bio has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does INmune Bio's 3-Year EBITDA Growth Rate compare to FLNA and DYAI?
According to the Biotechnology industry distribution chart, INmune Bio ranks #715 out of 1135 companies for 3-Year EBITDA Growth Rate. This places INmune Bio in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.80. INmune Bio's value of 5.00% is 66.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.80, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. INmune Bio's current 3-Year EBITDA Growth Rate of 5.00% is 66.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for INmune Bio and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. INmune Bio's current 3-Year EBITDA Growth Rate is 5.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is INmune Bio stock overvalued right now?
Based on GuruFocus' analysis, INmune Bio (INMB) is currently considered Fairly Valued. The stock's GF Value™ is $1.79, compared to a current price of $1.91 — trading 6.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 5.00% and 66.2% below the Biotechnology industry median of 14.80. INmune Bio's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For INmune Bio (INMB), the current 3-Year EBITDA Growth Rate is 5.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is INmune Bio (INMB) Overvalued in 2026?
Based on GuruFocus' analysis, INmune Bio stock appears to be overvalued.
The current stock price of $1.91 is trading 6.7% above its estimated GF Value™ of $1.79.
GuruFocus considers INmune Bio to be Fairly Valued.
Key valuation signals for INMB:
3-Year EBITDA Growth Rate: 5.00%
GF Value™: $1.79 vs. price of $1.91 (6.7% above fair value)
Industry Position: 66.2% below the Biotechnology median (#715 of 1135)
No single metric tells the full story. See the INMB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
58GF Score
Get the complete analysis for INMB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INMB has been successfully added to your 
